menu

Clinical Minute: Exploring the ARTEMIS 2 Study

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Clinical Minute: Exploring the ARTEMIS 2 Study

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Jason Bacharach, MD, sits down with Neda Shamie, MD, to discuss a randomized, 20-month, multicenter, masked, parallel-group, phase 3 trial that evaluated the IOP-lowering efficacy and safety of the bimatoprost implant (Durysta, Allergan) in patients with open-angle glaucoma or ocular hypertension. What were the results?

    To access the full review, please visit the link here.

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Jason Bacharach, MD, sits down with Neda Shamie, MD, to discuss a randomized, 20-month, multicenter, masked, parallel-group, phase 3 trial that evaluated the IOP-lowering efficacy and safety of the bimatoprost implant (Durysta, Allergan) in patients with open-angle glaucoma or ocular hypertension. What were the results?

    To access the full review, please visit the link here.

Facebook Comments

Schedule3 Oct 2023